首页|期刊导航|临床传统医学和药理学(英文)|健脾活血汤逆转慢性萎缩性胃炎肠化萎缩的临床疗效:一项随机对照试验

健脾活血汤逆转慢性萎缩性胃炎肠化萎缩的临床疗效:一项随机对照试验OA

Clinical effect of Jianpi Huoxue Decoction in reversing intestinal metaplasia and atrophy in chronic atrophic gastritis:A randomized controlled trial

中文摘要英文摘要

背景:慢性萎缩性胃炎以胃黏膜萎缩、肠化生为主要病理特征,是临床公认的胃癌前病变,目前现代医学尚无有效逆转该类病理改变的特异性治疗方案.中医学认为该病核心病机为"脾胃亏虚为本、胃络瘀阻为标",基于此病机,临床遵循"健脾益气固本、活血祛瘀通络"的核心治则开展辨证治疗.目的:该研究旨在观察常规西医基础治疗联合健脾活血方治疗慢性萎缩性胃炎的临床疗效,评估该中西医结合方案对患者临床症状、胃黏膜病理改变及胃分泌功能的干预效果.方法:该研究为前瞻性随机对照临床试验,遵循Consort 2025声明,招募2023年9月至2025年9月就诊的慢性萎缩性胃炎患者,随机分为治疗组与对照组.对照组采用叶酸片、维生素C片及对症处理的常规治疗,治疗组在对照组基础上,加用健脾活血方口服治疗,两组疗程均为3个月.对比两组患者治疗前后临床总有效率、中医证候积分、胃黏膜萎缩及肠化生病理分级(采用胃炎评价系统、肠化生评价系统评估)、胃分泌功能指标(胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ、胃蛋白酶原比值、胃泌素17)的变化.研究经浙江省杭州市临平区中医院伦理委员会批准(批号:2023050607),临床试验方案已在国际传统医学临床试验注册平台完成注册(注册号:ITMCTR2026000326,URL:https://itmctr.ccebtcm.org.cn/mgt/project/view/2020823963730575360).结果:治疗3个月后,治疗组临床总有效率显著高于对照组(93.1%vs.65.5%,P=0.005).治疗组胃脘痛、脘腹胀满、反酸等核心中医证候积分改善效果显著优于对照组(P<0.05).病理结果显示,治疗组胃黏膜萎缩改善率显著高于对照组(80%vs.46.7%,P<0.05),重度胃黏膜萎缩逆转率显著更高(57.9%vs.25.0%,P<0.05);两组整体肠化生改善率无明显差异,但治疗组重度肠化生逆转率显著优于对照组(52.4%vs.20.8%,P<0.05).胃功能指标方面,治疗组患者胃蛋白酶原Ⅰ、胃蛋白酶原比值显著升高,胃泌素17水平趋于正常化,各项指标改善程度显著优于对照组(P<0.001).结论:健脾活血方联合常规治疗具有显著协同增效作用,可有效改善慢性萎缩性胃炎患者的临床症状,逆转胃黏膜萎缩及重度肠化生病理改变,有效阻滞疾病进展,是临床治疗慢性萎缩性胃炎的有效中西医结合方案,具备良好的临床应用前景.

Background:Chronic atrophic gastritis(CAG),characterized by gastric mucosal atrophy and intestinal metaplasia,is a well-established precancerous lesion.Modern medicine currently lacks specific therapies to reverse these pathological changes.Traditional Chinese Medicine(TCM)posits that its core pathogenesis involves"spleen-stomach deficiency as the root cause and blood stasis in the stomach collaterals as the manifestation".Guided by this theory,this study employs the principle of"fortifying the spleen and replenishing qi to consolidate the root,and promoting blood circulation to remove stasis to unblock the collaterals"as the fundamental treatment approach.It aims to evaluate the clinical efficacy of the empirical formula Jianpi Huoxue Decoction(literally"Spleen-Fortifying and Blood-Activating Decoction")in combination with conventional Western medicine. Objective:This study aimed to evaluate the clinical efficacy of supplementing conventional Western medicine with Jianpi Huoxue Decoction in the treatment of chronic atrophic gastritis. Methods:This study was designed as a prospective randomized controlled clinical trial.The research followed the Consort 2025 statement,from September 2023 to September 2025,patients diagnosed with CAG were recruited and randomly assigned to a treatment group or a control group.The control group received conventional West-ern medicine treatment including folic acid tablets,vitamin C tablets,and symptomatic therapy.In addition to the same regimen administered to the control group,the treatment group received oral administration of Jianpi Huoxue Decoction.The treatment duration for both groups was three months.Clinical efficacy,TCM syndrome scores,histopathological grades of gastric mucosal atrophy and intestinal metaplasia(evaluated using Operative Link on Gastritis Assessment and Operative Link on Gastric Intestinal Metaplasia Assessment staging systems),and gastric secretion function indicators(PG I,PG Ⅱ,PGR,and G-17)were assessed and compared before and after treatment.The study protocol was approved by the Institutional Ethics Committee of Linping District Hos-pital of Traditional Chinese Medicine,Hangzhou,Zhejiang Province,China(Approval number:2023050607).The clinical trial protocol has been registered with the Chinese Clinical Trial Registry(ChiCTR)under the Inter-national Traditional Medicine Clinical Trial Registration Platform on February 9th,2026(registration number:ITMCTR2026000326,URL:https://itmctr.ccebtcm.org.cn/mgt/project/view/2020823963730575360). Results:After 3 months of treatment,the overall clinical effective rate was significantly higher in the treatment group than in the control group(93.1%vs.65.5%,P=0.005).The treatment group also showed greater im-provement in major TCM syndrome scores,including epigastric pain,abdominal fullness,and acid regurgitation(P<0.05).Histopathological evaluation demonstrated that the treatment group achieved a higher rate of gastric mucosal atrophy improvement compared with the control group(80%vs.46.7%,P<0.05).Moreover,regression from high-stage atrophy was more frequent in the treatment group(57.9%vs.25.0%,P<0.05).Although the overall improvement rate of intestinal metaplasia did not differ significantly between groups,the regression rate from high-stage intestinal metaplasia was significantly higher in the treatment group(52.4%vs.20.8%,P<0.05).In terms of gastric function,patients in the treatment group showed significant increases in pepsinogen Ⅰ(PG Ⅰ)and the pepsinogen ratio(PGR),along with a trend toward normalization of gastrin-17 levels,all of which were significantly better than those observed in the control group(P<0.001). Conclusion:Jianpi Huoxue Decoction demonstrates a synergistic effect when combined with conventional Western medicine.This integrated regimen not only effectively alleviates clinical symptoms in patients with CAG but also exerts a significant regression effect on gastric mucosal atrophy and intestinal metaplasia.These findings suggest that the combination of TCM and Western medicine can effectively intervene in disease progression,offering a promising clinical strategy for managing CAG.

岑刚;石荣珍;Tae-Young Choi;程时峰;凌鹏;王鑫炜;汪瑶;蒋群;来杰锋

杭州市临平区中医院,杭州 311106,浙江,中国杭州市临平区中医院塘栖分院,杭州 311106,浙江,中国KM Science Research Division,Korea Institute of Oriental Medicine,Yuseong-du,Daejeon 34054,Republic of Korea杭州市临平区中医院,杭州 311106,浙江,中国杭州市临平区中医院,杭州 311106,浙江,中国杭州市临平区中医院,杭州 311106,浙江,中国杭州市临平区中医院,杭州 311106,浙江,中国杭州市临平区中医院塘栖分院,杭州 311106,浙江,中国杭州市临平区中医院,杭州 311106,浙江,中国

慢性萎缩性胃炎健脾活血方中医药病理逆转中西医结合肠化生

Chronic atrophic gastritisJianpi Huoxue decoctionTraditional Chinese medicinePathological reversalIntegrated Chinese and Western medicineIntestinal metaplasia

《临床传统医学和药理学(英文)》 2026 (2)

10-22,13

This study was supported by the Hangzhou Health Science and Tech-nology Planning Project(No.B20231026)and the Traditional Chinese Medicine Clinical Research Project of Zhejiang Association of Tradi-tional Chinese Medicine(No.HQYTZY-2025-015).

10.1016/j.ctmp.2026.200283

评论